Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Accounts Payables (2020 - 2025)

Historic Accounts Payables for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Relay Therapeutics' Accounts Payables fell 5992.43% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 5992.43%. This contributed to the annual value of $14.1 million for FY2024, which is 5304.53% up from last year.
  • Per Relay Therapeutics' latest filing, its Accounts Payables stood at $2.8 million for Q3 2025, which was down 5992.43% from $5.2 million recorded in Q2 2025.
  • Relay Therapeutics' Accounts Payables' 5-year high stood at $14.8 million during Q2 2023, with a 5-year trough of $2.8 million in Q3 2025.
  • Its 5-year average for Accounts Payables is $8.7 million, with a median of $8.3 million in 2021.
  • As far as peak fluctuations go, Relay Therapeutics' Accounts Payables soared by 24399.44% in 2023, and later crashed by 5992.43% in 2025.
  • Over the past 5 years, Relay Therapeutics' Accounts Payables (Quarter) stood at $8.3 million in 2021, then grew by 27.82% to $10.6 million in 2022, then decreased by 12.92% to $9.2 million in 2023, then soared by 53.05% to $14.1 million in 2024, then tumbled by 80.48% to $2.8 million in 2025.
  • Its last three reported values are $2.8 million in Q3 2025, $5.2 million for Q2 2025, and $8.4 million during Q1 2025.